PPIDT00465

Drug Information
NameNirsevimab
SequenceQVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKFQGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLEGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DrugBank_IDDB16258
Typebiotech
IndicationNirsevimab is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season in Canada, the US, and Europe.[L44146,L46392] Additionally, Nirsevimab is also approved in Canada and the US for use in infants up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.[L46392, L47456] These infants include, but are not limited to, those with chronic lung disease of prematurity, hemodynamically significant congenital heart disease, immunocompromised states, Down syndrome, cystic fibrosis, neuromuscular disease, and congenital airway anomalies.[L46392]

Dosage Forms
Form Route Strength
Injection Intramuscular
100 mg/1mL
Injection Intramuscular
50 mg/0.5mL
Injection, solution Intramuscular
100 mg
Injection, solution Intramuscular
50 mg
Solution Intramuscular
100 mg / 1 mL
Solution Intramuscular
50 mg / 0.5 mL
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P13843 F Fusion glycoprotein F0 Human respiratory syncytial virus B (strain 18537) antibody Link
target P03420 F Fusion glycoprotein F0 Human respiratory syncytial virus A (strain A2) antibody Link
target P11209 F Fusion glycoprotein F0 Human respiratory syncytial virus A (strain RSS-2) antibody Link